<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:57:14Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10424280" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10424280</identifier>
        <datestamp>2023-08-14</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">101242342</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">32406</journal-id>
              <journal-id journal-id-type="nlm-ta">Contemp Clin Trials</journal-id>
              <journal-id journal-id-type="iso-abbrev">Contemp Clin Trials</journal-id>
              <journal-title-group>
                <journal-title>Contemporary clinical trials</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1551-7144</issn>
              <issn pub-type="epub">1559-2030</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10424280</article-id>
              <article-id pub-id-type="pmcid">PMC10424280</article-id>
              <article-id pub-id-type="pmc-uid">10424280</article-id>
              <article-id pub-id-type="pmid">34274495</article-id>
              <article-id pub-id-type="pmid">34274495</article-id>
              <article-id pub-id-type="doi">10.1016/j.cct.2021.106508</article-id>
              <article-id pub-id-type="manuscript">nihpa1920049</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sanft</surname>
                    <given-names>Tara</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                  <xref rid="CR1" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harrigan</surname>
                    <given-names>Maura</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cartmel</surname>
                    <given-names>Brenda</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ferrucci</surname>
                    <given-names>Leah M.</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Fang-Yong</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McGowan</surname>
                    <given-names>Courtney</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zupa</surname>
                    <given-names>Michelle</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nguyen</surname>
                    <given-names>Thai Hien</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ligibel</surname>
                    <given-names>Jennifer</given-names>
                  </name>
                  <xref rid="A4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Neuhouser</surname>
                    <given-names>Marian L.</given-names>
                  </name>
                  <xref rid="A5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hershman</surname>
                    <given-names>Dawn L.</given-names>
                  </name>
                  <xref rid="A6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Basen-Engquist</surname>
                    <given-names>Karen</given-names>
                  </name>
                  <xref rid="A7" ref-type="aff">g</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>Beth</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Knobf</surname>
                    <given-names>Tish</given-names>
                  </name>
                  <xref rid="A3" ref-type="aff">c</xref>
                  <xref rid="A8" ref-type="aff">h</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chagpar</surname>
                    <given-names>Anees</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Silber</surname>
                    <given-names>Andrea</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Irwin</surname>
                    <given-names>Melinda L.</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>a</label>Yale University School of Medicine, New Haven, CT, United States of America</aff>
              <aff id="A2"><label>b</label>Yale University School of Public Health, New Haven, CT, United States of America</aff>
              <aff id="A3"><label>c</label>Yale Cancer Center, New Haven, CT, United States of America</aff>
              <aff id="A4"><label>d</label>Dana-Farber Cancer Institute, Boston, MA, United States of America</aff>
              <aff id="A5"><label>e</label>Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America</aff>
              <aff id="A6"><label>f</label>Columbia University Medical Center, New York, NY, United States of America</aff>
              <aff id="A7"><label>g</label>The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America</aff>
              <aff id="A8"><label>h</label>Yale School of Nursing, New Haven, CT, United States of America</aff>
              <author-notes>
                <corresp id="CR1"><label>*</label>Corresponding author at: 333 Cedar Street, New Haven, CT 06510, United States of America. <email>tara.sanft@yale.edu</email></corresp>
                <fn fn-type="con" id="FN1">
                  <p id="P1">Author contributions</p>
                  <p id="P2"><italic toggle="yes">Tara Sanft</italic>: Writing: Conceptualization, Writing - original draft, Funding acquisition, Supervision, Investigation. <italic toggle="yes">Melinda Irwin:</italic> Conceptualization, Funding acquisition, Writing- Reviewing and Editing, Supervision, Investigation. <italic toggle="yes">Maura Harrigan:</italic> Conceptualization, Project administration, Resources, Investigation, Writing- Reviewing and Editing. <italic toggle="yes">Brenda Cartmel:</italic> Conceptualization, Project administration, Writing-Reviewing and Editing, Investigation. <italic toggle="yes">Leah M. Ferrucci:</italic> Conceptualization, Writing- Reviewing and Editing. <italic toggle="yes">Fang-Yong Li:</italic> Conceptualization, Methodology, Formal Analysis, Writing- Reviewing and Editing. <italic toggle="yes">Courtney McGowan:</italic> Investigation, Resources, Writing- Reviewing and Editing <italic toggle="yes">Michelle Zupa:</italic> Investigation, Resources Writing- Reviewing and Editing. <italic toggle="yes">Thai Hien Nguyen:</italic> Investigation, Resources, Writing- Reviewing and Editing. <italic toggle="yes">Jennifer Ligibel:</italic> Conceptualization, Writing- Reviewing and Editing. <italic toggle="yes">Marian L. Neuhouser:</italic> Conceptualization, Writing- Reviewing and Editing. <italic toggle="yes">Dawn L. Hershman:</italic> Conceptualization, Writing- Reviewing and Editing. <italic toggle="yes">Karen Basen-Engquist:</italic> Conceptualization, Writing-Reviewing and Editing. <italic toggle="yes">Beth Jones:</italic> Conceptualization, Writing-Reviewing and Editing. <italic toggle="yes">Tish Knobf:</italic> Conceptualization, Writing-Reviewing and Editing. <italic toggle="yes">Anees Chagpar:</italic> Conceptualization, Writing-Reviewing and Editing. <italic toggle="yes">Andrea Silber:</italic> Conceptualization, Writing-Reviewing and Editing.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>5</day>
                <month>8</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>10</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>16</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>14</day>
                <month>8</month>
                <year>2023</year>
              </pub-date>
              <volume>109</volume>
              <fpage>106508</fpage>
              <lpage>106508</lpage>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract id="ABS1">
                <sec id="S1">
                  <title>Background:</title>
                  <p id="P3">The World Cancer Research Fund and the American Cancer Society provide nutrition and physical activity guidelines for cancer survivors. Many women with breast cancer do not follow these guidelines and delay efforts toward following them until active treatment is complete. However, adoption of these recommended lifestyle behaviors soon after diagnosis may prevent adverse treatment-related side effects and may improve adherence to treatment, resulting in improved breast cancer prognosis. The <underline>L</underline>ifestyle, <underline>E</underline>xercise, and <underline>N</underline>utrition <underline>Ear</underline>ly after Diagnosis (LEANer) study is testing the effect of a nutrition and physical activity intervention on chemotherapy completion rates.</p>
                </sec>
                <sec id="S2">
                  <title>Methods:</title>
                  <p id="P4">172 women with stage I-III breast cancer undergoing chemotherapy will be randomized 1:1 to a yearlong, 16 session, nutrition and exercise intervention or usual care control group. The intervention is delivered by registered dietitians specializing in oncology nutrition and exercise training. The intervention includes goal setting to meet nutrition and physical activity guidelines for cancer survivors. After each chemotherapy session, date and dose of each drug administered, and reason for dose-adjustments and/or dose-delays are abstracted from the electronic medical record or obtained from the treating oncologist. Chemotherapy completion rate is assessed as the average relative dose-intensity (RDI) for the originally planned regimen based on standard formulas. Secondary endpoints of endocrine therapy adherence, treatment-related side effects, and changes in inflammatory and metabolic biomarkers, body composition, and patient reported outcomes are assessed at four timepoints.</p>
                </sec>
                <sec id="S3">
                  <title>Discussion:</title>
                  <p id="P5">If successful, this study has the potential to make healthy lifestyle interventions a standard component of breast cancer treatment.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Breast cancer</kwd>
                <kwd>Chemotherapy completion</kwd>
                <kwd>Nutrition</kwd>
                <kwd>Exercise</kwd>
                <kwd>Lifestyle</kwd>
                <kwd>Relative dose intensity</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="S4">
              <label>1.</label>
              <title>Introduction</title>
              <p id="P6">For lowering risk of breast cancer recurrence and mortality, the World Cancer Research Foundation (WCRF), the American Institute for Cancer Research (AICR), and the American Cancer Society (ACS) recommend following a dietary pattern that is high in vegetables, fruits, and whole grains; and an exercise regimen which includes 150 min per week of moderate-intensity exercise or 75 min of vigorous-intensity exercise plus two strength training sessions per week [<xref rid="R1" ref-type="bibr">1</xref>-<xref rid="R3" ref-type="bibr">3</xref>].</p>
              <p id="P7">A growing number of studies have evaluated the impact of following the recommended lifestyle behaviors on cancer risk and mortality [<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R7" ref-type="bibr">7</xref>]. For instance, the Vitamins and Lifestyle (VITAL) study showed that breast cancer risk was reduced by 60% in women who met the WCRF/AICR recommendations compared with those who did not meet the recommendations [<xref rid="R5" ref-type="bibr">5</xref>]. To our knowledge, no trial has examined in women newly diagnosed with breast cancer the effect of practicing the dietary and physical activity guidelines on chemotherapy completion rate and endocrine therapy adherence [<xref rid="R8" ref-type="bibr">8</xref>].</p>
              <p id="P8">Roughly 12–28% of breast cancer patients who initiate adjuvant chemotherapy discontinue early [<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]. Receipt of &lt;85% of the prescribed dose of chemotherapy, which may be due to either early discontinuation or dose reduction, is associated with worse relapse-free and overall survival [<xref rid="R11" ref-type="bibr">11</xref>-<xref rid="R14" ref-type="bibr">14</xref>].</p>
              <p id="P9">Few studies have examined how lifestyle behaviors may impact chemotherapy completion rates as a primary aim. We recently completed a retrospective chart review of body mass index (BMI) and physical activity on chemotherapy completion rate in 243 women receiving chemotherapy. Physical activity was associated with completion of chemotherapy (OR 7.6, 95% CI 1.4–41.2, <italic toggle="yes">P</italic> = 0.02) [<xref rid="R15" ref-type="bibr">15</xref>].</p>
              <p id="P10">There is a need to more fully evaluate the role of adherence to nutrition and physical activity guidelines on chemotherapy completion rates. The <underline>L</underline>ifestyle, <underline>E</underline>xercise <underline>A</underline>nd <underline>N</underline>utrition <underline>Ear</underline>ly after Diagnosis (LEANer) study is designed to test the effect of a nutrition and physical activity intervention on rates of chemotherapy completion and adherence to endocrine therapy, as well as treatment-related side effects and changes in biomarkers, body composition and patient-reported outcomes, in women with early stage breast cancer.</p>
            </sec>
            <sec id="S5">
              <label>2.</label>
              <title>Materials and methods</title>
              <sec id="S6">
                <label>2.1.</label>
                <title>Primary aim</title>
                <p id="P11">LEANer is a randomized controlled trial investigating the effect of a nutrition and physical activity intervention vs. usual care on chemotherapy completion rates in women with early stage breast cancer (<xref rid="F1" ref-type="fig">Fig. 1</xref>).</p>
              </sec>
              <sec id="S7">
                <label>2.2.</label>
                <title>Secondary aims</title>
                <p id="P12">Secondary aims include examining the impact of the intervention vs. usual care on endocrine therapy adherence, body composition, serum biomarkers, treatment-related side effects and patient-reported outcomes.</p>
              </sec>
              <sec id="S8">
                <label>2.3.</label>
                <title>Design</title>
                <p id="P13">Target enrollment is 172 women with stage I-III breast cancer undergoing chemotherapy (neoadjuvant or adjuvant) for curative intent. The trial funder is the National Cancer Institute (NCI). Participants are randomized 1:1 to a 12 month in-person and telephone-based intervention or a usual care control group. Usual care was selected as a comparator as it limits contact with study personnel and thus minimizes change in behavior due to study participation. Patients are enrolled through the Smilow Cancer Hospital Network at Yale-New Haven Hospital and through the Dana-Farber Cancer Institute in Boston, MA. The intervention is delivered in-person, by telephone or via a combination of in-person and telephone-based sessions by the Yale-based registered dietitians (RDs). The trial aims for robust minority enrollment with study team members playing leadership roles focused on diversity and clinical trial enrollment, and partnerships with clinicians whose practices predominantly serve minority populations. The study enrollment, interventions and assessments are shown in <xref rid="F2" ref-type="fig">Fig. 2</xref>. The Yale Human Investigation Committee (IRB) and the Dana-Farber Cancer Institute Institutional Review Board approved informed consent and all relevant procedures. Informed consent will be obtained from all participants.</p>
              </sec>
              <sec id="S9">
                <label>2.4.</label>
                <title>Eligibility</title>
                <p id="P14">Women with stage I-III breast cancer undergoing neoadjuvant or adjuvant chemotherapy who are able to walk and not meeting the recommended diet and physical activity guidelines are eligible (<xref rid="T1" ref-type="table">Table 1</xref>).</p>
              </sec>
              <sec id="S10">
                <label>2.5.</label>
                <title>Screening questionnaire</title>
                <p id="P15">Eligibility criteria are determined from electronic medical records (EMR) and via interview-administered questionnaires, which are conducted following the in-person or telephone consent discussion, conducted by one of the study staff, and receipt of informed consent. Screening includes determining eligibility on diet and physical activity by asking the following questions: 1. ‘Prior to your diagnosis of breast cancer, did you exercise, (for example, jogging, brisk walking for exercise or stationary bicycling)?’ If the patient reports exercising less than 150 min per week of moderate-intensity aerobic exercise or less than 75 min per week of vigorous-intensity aerobic exercise or an equivalent combination they are coded ‘no’ on the exercise criteria; 2a. ‘Prior to your diagnosis of breast cancer, how many servings of vegetables did you usually eat per day? and 2b. ‘Prior to your diagnosis of breast cancer, how many servings of fruit did you usually eat per day?’ Eligibility criterium for fruit and vegetable intake: less than 7 fruit and vegetable servings combined per day. If the patient reports eating less than 7 fruits and vegetable servings per day, they are coded ‘no’ on the healthy eating criteria. To be eligible, participants need to respond ‘No’ to both questions. This simple question approach has been endorsed by others [<xref rid="R16" ref-type="bibr">16</xref>] and we have used it as screening criteria in our other nutrition and physical activity trials [<xref rid="R17" ref-type="bibr">17</xref>].</p>
              </sec>
              <sec id="S11">
                <label>2.6.</label>
                <title>Randomization and stratification</title>
                <p id="P16">Eligible women are randomized to either intervention or usual care in a 1:1 ratio, stratified by HER2 status (+ or −), Hormone Receptor (HR + or −) status, and number of chemotherapy cycles for HER2 negative patients (4 cycles or 5 or more). In total six strata are used:</p>
                <list list-type="bullet" id="L2">
                  <list-item>
                    <p id="P17">HER2−, HR +, 4 cycles</p>
                  </list-item>
                  <list-item>
                    <p id="P18">HER2−, HR +, 5 or more cycles</p>
                  </list-item>
                  <list-item>
                    <p id="P19">HER2−, HR−, 4 cycles</p>
                  </list-item>
                  <list-item>
                    <p id="P20">HER2−, HR−, 5 or more cycles</p>
                  </list-item>
                  <list-item>
                    <p id="P21">HER2 +, HR +</p>
                  </list-item>
                  <list-item>
                    <p id="P22">HER2 +, HR−</p>
                  </list-item>
                </list>
                <p id="P23">The randomization list was generated for each stratum by computer using the permutation method with variable block sizes. After completion of the baseline assessments, eligible patients are randomized by a member of the Yale research staff. Sealed envelopes containing the random allocation are prepared by an individual who is not affiliated with the study and opened at the point of randomization. The individuals conducting the dual energy X-ray absorptiometry (DXA) scan and the laboratory biomarker analysis are blinded to the randomization group.</p>
              </sec>
            </sec>
            <sec id="S12">
              <label>3.</label>
              <title>Study intervention</title>
              <sec id="S13">
                <label>3.1.</label>
                <title>Setting</title>
                <p id="P24">Women can be enrolled and initiate the intervention any time prior to their second chemotherapy. The intervention schedule of sixteen 30-min sessions over 12 months follows the participant through the trajectory of their active treatment (3 times in the first month, 2 times each month for months 2 through 5, and 5 times over the next 6 months). Our previous Lifestyle, Exercise and Nutrition (LEAN) trial, conducted in the post-treatment setting, compared in-person counseling to telephone-counseling and found no between-group difference in intervention adherence, with both the in-person and telephone-based intervention groups experiencing similar favorable changes in physical activity, diet, body weight and serum biomarkers [<xref rid="R18" ref-type="bibr">18</xref>]. Thus, for the LEANer study, all intervention sessions can be completed either in-person or by telephone, as per participant preference or as determined by study site location and COVID-19 restrictions. Independent of study arm, all concomitant care and interventions are permitted during the study intervention (year 1) and follow-up (year 2).</p>
              </sec>
              <sec id="S14">
                <label>3.2.</label>
                <title>Content of counseling sessions</title>
                <p id="P25">The intervention is based on the LEAN protocol [<xref rid="R18" ref-type="bibr">18</xref>], which was developed by Drs. Irwin, Sanft and Ms. Harrigan, adapted from the Diabetes Prevention Program [<xref rid="R19" ref-type="bibr">19</xref>] and further adapted to meet the unique concerns of breast cancer patients in active treatment, most notably the prevention of chemotherapy side effects and weight gain. All counseling sessions are conducted by RDs who are Certified Specialists in Oncology Nutrition (CSO) by the Academy of Nutrition and Dietetics [<xref rid="R20" ref-type="bibr">20</xref>], with additional training in exercise science. The intervention represents a core curriculum, using motivational counseling to address behavior strategies such as self-monitoring, goal setting, stimulus control, problem solving, and relapse prevention training. The intervention sessions are based on constructs of social-cognitive theory. The nutrition counseling promotes a predominantly plant-based diet with modifications to food texture, flavor and selection of tolerated nutrient-dense foods made on an individual basis to ensure adequate macronutrient and micronutrient food intake, and optimal glucose management.</p>
                <p id="P26">Women receive our 16-chapter workbook adapted from the LEAN Study with skill building self-care topics across the trajectory of active treatment including: anticipating, tracking and managing treatment side effects; importance of hydration and managing liquid sugars; managing fatigue through exercise, meal timing and meal composition; managing expectations of others; comfort eating; the importance of nutrition and exercise with endocrine therapy and the late effects of treatment including cardiac health, lymphedema, fatigue, fear of food, and fear of recurrence. All 16 chapters are accompanied by a homework assignment; of these, recording daily food intake and physical activity are the most important.</p>
                <p id="P27">We developed a Nutrition Impact Symptom (NIS) Management Recipe Book which contains 45 recipes kitchen-tested and adapted to the unique nutrition concerns of breast cancer patients to promote weight management and prevention of weight gain. Recipes are nutrient dense, low in added sugars, with soft textures to manage specific NIS of active treatment: xerostomia, mucositis, dysgeusia, dysphagia, nausea, vomiting, diarrhea, constipation, anorexia and fatigue.</p>
              </sec>
              <sec id="S15">
                <label>3.3.</label>
                <title>Physical activity</title>
                <p id="P28">The physical activity program, similar to our previous studies, relies on home-based exercise, with an emphasis on brisk walking and reaching a goal of 150 min per week of moderate-intensity exercise and 10,000 steps walked each day. Reducing sedentary behaviors is also encouraged through activities of daily living (see <xref rid="T2" ref-type="table">Table 2</xref>). The LEAN program increased physical activity levels by 116 min per week compared to 18 min per week among women randomized to usual care (<italic toggle="yes">p</italic> &lt; 0.01) [<xref rid="R18" ref-type="bibr">18</xref>]. For the LEANer trial, we have enhanced the physical activity program offered in LEAN, by including a home-based progressive strength training program. Each participant randomized to intervention is given a set of dumbbells (3, 5 and 8 lbs.) to use at home. Patients are instructed during each counseling session to progressively increase repetitions and weight, individualized to their ability. The counseling is supported by a video of the LEANer Stretching, Core Exercises and Strength Training routine, which is posted on the study website.</p>
                <p id="P29">All exercises are demonstrated and narrated by an American College of Sports Medicine Certified Cancer Exercise Trainer. Participants record the type and duration of exercise they do in their log book provided to them. We also include a tool-box approach, as was done in the Diabetes Prevention Program, where we provide participants with an optional 1-year membership to a YMCA that also offers the Livestrong Program [<xref rid="R21" ref-type="bibr">21</xref>] and Fitbits to motivate participants to increase their daily exercise.</p>
              </sec>
              <sec id="S16">
                <label>3.4.</label>
                <title>Intervention goals</title>
                <p id="P30">The goal of the intervention is for participants to adopt and practice the recommended dietary and physical activity guidelines. We measure adherence to the dietary guidelines by whether participants meet the Healthy Eating Index 2015 (HEI-2015), as it aligns with the USDA’s 2016 Dietary Guidelines for Americans (DGA), and has been found to be a valid and reliable measure of diet quality. We will also evaluate changes in intake of food group, total energy and energy from fat. Adherence to the physical activity guidelines is determined from a physical activity questionnaire completed at the follow-up visits. A combined “healthy behavior” score will be calculated for each individual and compared from baseline to end of study to assess change in adherence to nutrition and physical activity guidelines.</p>
              </sec>
            </sec>
            <sec id="S17">
              <label>4.</label>
              <title>Usual care</title>
              <p id="P31">During the trial, participants will only be contacted to complete the assessments. The usual care group has access to a RD at any time throughout treatment; referral is at the discretion of the treating oncologist. At the end of the study, usual care participants are offered an individualized diet and physical activity counseling session with a RD and receive a copy of the study materials. In addition, all participants, including the usual care participants, are referred to the Yale Cancer Center Survivorship Clinic or are able to access the Zakim Center for Integrative Therapies at Dana-Farber Cancer Institute.</p>
            </sec>
            <sec id="S18">
              <label>5.</label>
              <title>Study assessments</title>
              <sec id="S19">
                <label>5.1.</label>
                <title>Analysis of chemotherapy completion rate</title>
                <p id="P32">At the completion of each woman’s chemotherapy session, data including date and dose of each drug administered, and reason for dose-adjustments and dose-delays are abstracted from the electronic medical record, or, if necessary, obtained from the treating oncologist. Chemotherapy completion rate will be assessed as the average relative dose-intensity (RDI) for the originally planned regimen based on standard formulas below [<xref rid="R22" ref-type="bibr">22</xref>]. Relative dose intensity (RDI) was defined as the ratio of actual dose intensity to projected dose intensity, expressing as a percentage or proportion of the amount of drug planned to deliver per weeks (mg/m2•week). The projected DI is calculated by:
<disp-formula id="FD1"><mml:math id="M1" display="block"><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>d</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mi>g</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>S</mml:mi><mml:mi>A</mml:mi><mml:mo>×</mml:mo><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>w</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mi>k</mml:mi><mml:mi>s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula>
where BSA stands for body surface area (m2). And the actual DI is calculated by:
<disp-formula id="FD2"><mml:math id="M2" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>d</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mi>g</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>S</mml:mi><mml:mi>A</mml:mi><mml:mo>×</mml:mo><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>w</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mi>k</mml:mi><mml:mi>s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p>
                <p id="P33">RDI will be calculated for each drug separately. The average RDI will be used as outcome measure for each patient.</p>
                <p id="P34">We will measure the number and percent of patients who have dose-adjustments or delays, the reason for the dose-adjustment/dose delays (e.g. neuropathy or vacation) and the percent dose reduction for each participant.</p>
              </sec>
              <sec id="S20">
                <label>5.2.</label>
                <title>Patient reported outcomes</title>
                <p id="P35">Women are asked to complete self-administered study questionnaires prior to randomization, after completion of chemotherapy, 1- and 2-years post-randomization. Women are provided a link via email to the online questionnaires or given a hard copy version if preferred. Dietary intake over the past 3 months is assessed via a self-administered food frequency questionnaire [<xref rid="R23" ref-type="bibr">23</xref>]. Participants complete an interview-administered physical activity questionnaire. The past 3 months of physical activity, including the type, frequency and duration of 20 activities are assessed [<xref rid="R24" ref-type="bibr">24</xref>]. Additional patient reported assessments include endocrine therapy adherence, quality of life, neuropathy, patient reported outcomes, adherence to medication, lymphedema and employment experience. A subset of patients is asked to complete the 24-h dietary recall interviews.</p>
              </sec>
              <sec id="S21">
                <label>5.3.</label>
                <title>Assessment of body composition, biomarkers and endocrine therapy adherence</title>
                <p id="P36">At each of the four timepoints, women treated at Smilow Cancer Hospital Network are invited to complete in-person assessments, which are conducted at the Hospital Research Unit of Yale-New Haven Hospital. In-person procedures include: fasting blood draw to assess serum metabolic and inflammatory biomarkers, dual-energy X-ray absorptiometry scan to assess body composition, algometry to assess grip strength, skin carotenoid assessment [<xref rid="R25" ref-type="bibr">25</xref>], anthropometry (height, weight, waist and hip circumference) and urine collection for women who are prescribed aromatase inhibitors to assess compliance. Women are also asked to collect a stool sample. All assessments are described in <xref rid="F2" ref-type="fig">Fig. 2</xref> [<xref rid="R31" ref-type="bibr">31</xref>-<xref rid="R37" ref-type="bibr">37</xref>]</p>
              </sec>
            </sec>
            <sec id="S22">
              <label>6.</label>
              <title>Statistical considerations</title>
              <sec id="S23">
                <label>6.1.</label>
                <title>Power and sample size considerations</title>
                <p id="P37">The sample size estimate was performed using PASS 12 (©2013 NCSS, LLC, Kayesvile, UT). The original calculation was based on chemotherapy completion rates reported in the Compliance in Adjuvant treatment in primary breast cancer Study (COMPAS) study [<xref rid="R26" ref-type="bibr">26</xref>]. By assuming similar completion rate in our control arm, we estimated a sample size of 250 subjects would be needed. Sample size reevaluation was conducted using the aggregated data of the first 51 LEANer participants who completed chemotherapy. This allowed us to have better accuracy in RDI variation in our patients. RDI was analyzed as continuous variable with a pooled standard deviation of 0.10. We re-estimated that a sample size of 86 subjects per arm (<italic toggle="yes">n</italic> = 172) will achieve 90% power to detect a 0.05 (or 5%) difference in RDI between two arms at significance level of 0.05, using two-sided two-sample equal-variance <italic toggle="yes">t</italic>-test.</p>
                <p id="P38">For endocrine therapy adherence, the COMPAS study reported 48% of patients in the control group were adhering to AI therapy at 12 months [<xref rid="R26" ref-type="bibr">26</xref>]. We assume approximately 50% of patients randomized to usual care in our study will be adhering to endocrine therapy at two years post randomization (approximately one-year post-initiation of use). We estimate 70% of participants (i.e., 70% of 172 = 120) will be prescribed endocrine therapy; thus an <italic toggle="yes">N</italic> = 120 will also allow for 80% power to detect a 24% absolute increase in adherence in intervention group at alpha level of 0.05, or a 29% absolute increase at alpha level of <bold>0.01.</bold></p>
              </sec>
              <sec id="S24">
                <label>6.2.</label>
                <title>Statistical analyses plan</title>
                <p id="P39">The study design is a two-arm superiority randomized controlled trial. The primary endpoint is RDI. RDI will be calculated using the methods described by Longo et al. [<xref rid="R22" ref-type="bibr">22</xref>]. The primary endpoint of RDI will be analyzed both as a continuous scale using a t-test, and as a dichotomized outcome using 85% or 95% cut-off for Mantel-Haensel chi-square test while controlling for stratification factors. Group differences in chemotherapy completion will be analyzed with binary logistic regression analysis; whether or not having dose reduction during the period of chemotherapy treatment (the period between T0 and T1) will be the dichotomized dependent variable.</p>
                <p id="P40">The secondary outcomes including endocrine therapy adherence, body compositions and biomarkers. The outcome of endocrine therapy adherence will be assessed at the 2-year visit (as most, if not all, participants prescribed endocrine therapy will have been taking it for at least one year at this 2-year visit, allowing us to assess adherence to endocrine therapy). An undetectable urine AI level will classify them as nonadherent to AIs [<xref rid="R26" ref-type="bibr">26</xref>]. Our secondary measure of endocrine therapy adherence will be based on the following questions: (1) “In the past month, how often did you take your medications as the doctor prescribed?” Possible responses are: all of the time (100%), nearly all of the time (90%), most of the time (75%), about half the time (50%), or less than half the time (&lt;50%). Nonadherence is defined as 75% of the time or less. (2) “In the past month, how often did you forget to take 1 or more of your prescribed medications?” Possible responses were never, once in the past month, 2 to 3 times in the past month, once per week, several times per week, and nearly every day. Nonadherence is defined as forgetting to take prescribed medications once per week or more. (3) “In the past month, how often did you decide to skip 1 or more of your prescribed medications?” Possible responses were the same as for question 2. Nonadherence is defined as deciding to skip medications once per week or more [<xref rid="R27" ref-type="bibr">27</xref>]. Participants who report that they have discontinued taking tamoxifen or AI will also be classified as nonadherent to endocrine therapy. For the endocrine therapy aim, we will compare the crude adherence rates using simple logistic regression. Multivariate logistic regression will serve as supportive analyses including covariate adjustments – which are similar to the primary analysis above.</p>
                <p id="P41">The other secondary outcomes will be performed using Mixed Model Repeated Measures analysis incorporating Analysis of Covariance, where each woman’s changes in outcome (follow-up measure – baseline) will be modeled as a function of treatment and time (fixed effects) with the baseline value and stratification factors as covariates. Prior to fitting models, we will perform exploratory data analyses focusing on the distributions of biological markers by time and intervention group, assessing the appropriateness of log-transformation.</p>
                <p id="P42">All hypotheses will be tested according to the intention-to-treat philosophy in which all randomized participants will be grouped according to their intervention assignment at randomization, regardless of compliance or adherence to the study. Statistical significance will be defined as <italic toggle="yes">p</italic> &lt; 0.05, 2-sided. Since we have multiple outcomes, we will consider using a Bonferroni correction.</p>
                <p id="P43">Age, menopausal status, race/ethnicity, BMI at diagnosis, disease stage, type of surgery, type of chemotherapy, neoadjuvant/adjuvant chemotherapy, radiation therapy, HR status, HER2 status, endocrine therapy, reconstructive surgery, type 2 diabetes, smoking status and study site will be examined as covariates. We will explore effect modification by menopausal status at diagnosis, hormone receptor status, and endocrine therapy. We will further explore intervention effects on study endpoints by stratifying by adherence to diet and physical activity guidelines with a multi-level category (e.g., met diet recommendations, met physical activity, met both diet and physical activity recommendations, or met neither recommendation). This analysis will allow us to better understand the role of diet vs. exercise on study endpoints.</p>
                <p id="P44">Although we do not anticipate an appreciable number of subjects lost-to-follow-up because of our plan of following patients during their medical oncology visits, the impact of missing data will be evaluated in the analysis. Bivariate logistic regression will be used to identify baseline variables associated with missingness. The primary analysis assumes missing data are missing at random (MAR). Under the MAR missing data mechanism, the probability of loss-to-follow-up depends only on the observed data. Mixed effects model analysis using maximum-likelihood estimation method is an efficient way to handle MAR data [<xref rid="R38" ref-type="bibr">38</xref>]. Non-random or informative loss-to-follow-up occurs when the missing data are dependent on the unobserved missing outcome values, latent and/or instrumental variables. Sensitivity analyses using methods for not missing at random (NMAR) data will be considered.</p>
              </sec>
            </sec>
            <sec id="S25">
              <label>7.</label>
              <title>Data management</title>
              <p id="P45">Participants will complete online questionnaires using a secure HIPAA-compliant service (Qualtrics) or via mailed paper questionnaires. Study data is stored on a secure server which is maintained by Yale University Medical School. Database access is limited by individual ID and password. The primary outcome data is entered in duplicate by different staff members and is reconciled by a third staff member.</p>
            </sec>
            <sec id="S26">
              <label>8.</label>
              <title>Data and safety monitoring</title>
              <p id="P46">As the study is considered minimal risk, the principal investigator (TS) is responsible for monitoring the data, assuring protocol compliance, and conducting the safety reviews. During the review process the principal investigator will evaluate whether the study should continue unchanged, require modification/amendment, or close to enrollment. A log of adverse events will be maintained by the study staff and reviewed on a regular basis by the principal investigator (TS), serious adverse events will be reported as per IRB guidance. Adverse events will be categorized and summarized by intervention arms using counts and proportions. The exact binomial test will be considered. The study protocol will be reviewed on an annual basis by the relevant IRBs. Protocol changes will be communicated to relevant parties via weekly team meetings and timely email communications. A routine review will be conducted annually by the Office of Quality Assurance &amp; Monitoring, Yale Center for Clinical Investigation.</p>
            </sec>
            <sec id="S27">
              <label>9.</label>
              <title>Discussion</title>
              <p id="P47">Higher levels of physical activity and lower body mass index (BMI) have been shown to be associated with better adherence to chemotherapy completion rate and increased pathological response rate, respectively, in women with breast cancer receiving neoadjuvant chemotherapy [<xref rid="R15" ref-type="bibr">15</xref>]. Thus, lifestyle behavioral interventions to improve diet and increase physical activity have the potential to improve response to chemotherapy, potentially via improvement in compliance to chemotherapy.</p>
              <p id="P48">Van Waart and colleagues evaluated the effect of a home-based, low-intensity physical activity program (Onco-Move) and a supervised, moderate- to high-intensity, combined resistance and aerobic exercise program (OnTrack) compared to usual care on chemotherapy completion rates [<xref rid="R28" ref-type="bibr">28</xref>]. Based on their medical record review, the planned chemotherapy regimens and schedules of the three groups were similar and included combinations of anthracyclines, taxanes, alkylating agents, and antimetabolites. In total, 61 of 230 patients (27%) required chemotherapy dose adjustments, with a smaller percentage of OnTrack participants requiring chemotherapy dose adjustments (12%) than those in the Onco-Move (34%) or usual care group (34%), <italic toggle="yes">p</italic> = 0.002. The average dose reduction among those who required chemotherapy adjustment in OnTrack and Onco-Move was 10%, compared with 25% in usual care; <italic toggle="yes">p</italic> = 0.014, with neuropathy being the primary reason for dose adjustments. Similarly, Courneya and colleagues’ conducted an exercise trial in 242 breast cancer survivors initiating adjuvant chemotherapy [<xref rid="R29" ref-type="bibr">29</xref>]. Women were randomly assigned to usual care (<italic toggle="yes">n</italic> = 82), supervised resistance exercise (n = 82), or supervised aerobic exercise (<italic toggle="yes">n</italic> = 78) for the duration of their chemotherapy (median, 17 weeks; 95% CI, 9 to 24 weeks). While the primary endpoint was quality of life, a secondary endpoint was chemotherapy completion rate. Adjusted mixed-models analyses indicated that resistance exercise was superior to usual care for improving chemotherapy completion rate (<italic toggle="yes">p</italic> = 0.033). Relative dose-intensity was 84% in the usual care group compared with 90% in the resistance exercise group (p = 0.033) and 87% in the aerobic exercise group (<italic toggle="yes">p</italic> = 0.266). The percentage of participants who received at least 85% of their planned dose-intensity was 66% in the usual care group compared with 78% in the resistance exercise group (<italic toggle="yes">p</italic> = 0.082) and 74% in the aerobic exercise group (<italic toggle="yes">p</italic> = 0.241).</p>
              <p id="P49">Carayol et al. [<xref rid="R30" ref-type="bibr">30</xref>] recently reported a beneficial effect of a physical activity and nutrition intervention vs. usual care on patient reported outcomes in 143 early stage breast cancer patients receiving chemotherapy. The intervention included thrice-weekly moderate-intensity mixed aerobic and resistance exercise sessions and 9 nutrition consultations. Chemotherapy completion rate was reported as a secondary endpoint. No difference between groups was seen for the relative dose intensity (96.7% in the intervention arm versus 96% in usual care arm; <italic toggle="yes">p</italic> = 0.39); however, a higher percentage of patients in the intervention arm (78.8%) received more than 95% of their planned relative dose intensity compared to the usual care arm (65.1%), <italic toggle="yes">p</italic> = 0.08. While Carayol’s trial is suggestive of an effect of nutrition and exercise on improving chemotherapy completion rate, given the secondary aim, it is likely that reasons for chemotherapy dose delays or adjustments were not taken into consideration. To our knowledge, the LEANer study is the first randomized nutrition and exercise intervention to be administered during chemotherapy with the primary aim of improving chemotherapy completion rates. Our approach includes a detailed EMR review and real-time follow-up with the oncologist to document reasons for chemotherapy dose delays or adjustments.</p>
              <p id="P50">In addition, improving nutrition and physical activity levels show promise for improving adherence to endocrine therapy, in turn improving breast cancer survival. We completed a randomized controlled exercise trial on side effects of aromatase inhibitors including arthralgias and found exercise to improve arthralgias by 29% compared to a 3% worsening in usual care (<italic toggle="yes">p</italic> &lt; 0.001). Arthralgias are a common and primary reason for poor adherence to aromatase inhibitors. The LEANer study will examine the impact of nutrition and exercise on side effects of endocrine therapy as well as adherence to endocrine therapy.</p>
              <p id="P51">Ultimately, if our study finds that adopting and following the dietary and physical activity guidelines improves adherence to chemotherapy and endocrine therapy, serum biomarkers, body composition and patient reported outcomes, then lifestyle behavioral counseling may become a standard of care in breast cancer treatment, in turn impacting obesity rates, treatment-related side effects and improved disease-free survival.</p>
            </sec>
          </body>
          <back>
            <ack id="S29">
              <title>Funding</title>
              <p id="P53">This study is supported by the National Cancer Institute of the National Institutes of Health [grant number 1R01CA207753]; the Breast Cancer Research Foundation; the Yale Cancer Center Support Grant [P30 CA016359]; and the National Center for Advancing Translational Science [grant number UL1 TR000142].</p>
            </ack>
            <fn-group>
              <fn id="FN2">
                <p id="P54">Trial registration</p>
                <p id="P55"><ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link>. Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03314688" ext-link-type="uri">NCT03314688</ext-link> Registered October 19, 2017, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03314688?term=NCT03314688&amp;draw=2&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT03314688?term=NCT03314688&amp;draw=2&amp;rank=1</ext-link></p>
              </fn>
              <fn id="FN3">
                <p id="P56">Declaration of Competing Interest</p>
                <p id="P57">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability" id="S28">
              <title>Data statement</title>
              <p id="P52">T.S. and M.L.I. are the guarantors of the research data and material described in this manuscript. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.</p>
            </sec>
            <glossary>
              <title>Abbreviations:</title>
              <def-list>
                <def-item>
                  <term>ACS</term>
                  <def>
                    <p id="P58">American Cancer Society</p>
                  </def>
                </def-item>
                <def-item>
                  <term>AI</term>
                  <def>
                    <p id="P59">Aromatase Inhibitor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>AICR</term>
                  <def>
                    <p id="P60">American Institute of Cancer Prevention</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BCPT</term>
                  <def>
                    <p id="P61">Breast cancer prevention trial</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BMI</term>
                  <def>
                    <p id="P62">Body Mass Index</p>
                  </def>
                </def-item>
                <def-item>
                  <term>COMPAS</term>
                  <def>
                    <p id="P63">Compliance in adjuvant treatment in primary breast cancer study</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CPS-II</term>
                  <def>
                    <p id="P64">Cancer prevention study-II</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CSO</term>
                  <def>
                    <p id="P65">Certified specialist in oncology nutrition</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DGS</term>
                  <def>
                    <p id="P66">Dietary guidelines for Americans</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DHHS</term>
                  <def>
                    <p id="P67">U.S. Department of Health and Human Services</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DXA</term>
                  <def>
                    <p id="P68">Dual energy X-ray absorptiometry</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EORTC QLQ-CIPN</term>
                  <def>
                    <p id="P69">European Organization for Research and Treatment of Cancer, quality of life questionnaire-chemotherapy-induced peripheral neuropathy</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IRB</term>
                  <def>
                    <p id="P70">Institutional Review Board</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HEI-2015</term>
                  <def>
                    <p id="P71">Healthy eating index 2015</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HR</term>
                  <def>
                    <p id="P72">Hormone receptor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LEANer</term>
                  <def>
                    <p id="P73">Lifestyle Exercise and Nutrition Early after Diagnosis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RDI</term>
                  <def>
                    <p id="P74">Relative dose-intensity</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NCI</term>
                  <def>
                    <p id="P75">National Cancer Institute</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RD</term>
                  <def>
                    <p id="P76">Registered dietitian</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LEAN</term>
                  <def>
                    <p id="P77">Lifestyle, Exercise and Nutrition</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MAR</term>
                  <def>
                    <p id="P78">Missing at random</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NIS</term>
                  <def>
                    <p id="P79">Nutrition impact symptom</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NMAR</term>
                  <def>
                    <p id="P80">Not missing at random</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PROMIS</term>
                  <def>
                    <p id="P81">Patient-reported outcomes measurement information system</p>
                  </def>
                </def-item>
                <def-item>
                  <term>VITAL</term>
                  <def>
                    <p id="P82">Vitamins and lifestyle study</p>
                  </def>
                </def-item>
                <def-item>
                  <term>WCRF</term>
                  <def>
                    <p id="P83">The World Cancer Research Fund</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>[1]</label>
                <mixed-citation publication-type="book"><collab>Dietary Guidelines for Americans 2010</collab>, <source>U.S. Department of Agriculture USDoHaHS</source>, <publisher-name>US Government Printing Office</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>, <year>2010</year>.</mixed-citation>
              </ref>
              <ref id="R2">
                <label>[2]</label>
                <mixed-citation publication-type="journal"><name><surname>Cheryl</surname><given-names>L</given-names></name>, <name><surname>Rock</surname><given-names>CD</given-names></name>, <name><surname>Demark-Wahnefried</surname><given-names>Wendy</given-names></name>, <name><surname>Meyerhardt</surname><given-names>Jeffrey</given-names></name>, <name><surname>Courneya</surname><given-names>Kerry S.</given-names></name>, <name><surname>Schwartz</surname><given-names>Anna L.</given-names></name>, <name><surname>Bandera</surname><given-names>Elisa V.</given-names></name>, <name><surname>Hamilton</surname><given-names>Kathryn K.</given-names></name>, <name><surname>Grant</surname><given-names>Barbara</given-names></name>, <name><surname>McCullough</surname><given-names>Marji</given-names></name>, <name><surname>Byers</surname><given-names>Tim</given-names></name>, <name><surname>Gansler</surname><given-names>Ted</given-names></name>, <article-title>Nutrition and physical activity guidelines for cancer survivors</article-title>, <source>CA Cancer J. Clin</source><volume>62</volume> (<issue>4</issue>) (<year>2012</year>) <fpage>213</fpage>–<lpage>277</lpage>, <pub-id pub-id-type="doi">10.3322/caac.21142</pub-id>.<pub-id pub-id-type="pmid">22619106</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>[3]</label>
                <mixed-citation publication-type="book"><collab>Research AIfC</collab> (Ed.), <source>Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective</source>, <publisher-name>World Cancer Research Fund International</publisher-name>, <publisher-loc>Washington DC</publisher-loc>, <year>2007</year>.</mixed-citation>
              </ref>
              <ref id="R4">
                <label>[4]</label>
                <mixed-citation publication-type="journal"><name><surname>Marjorie</surname><given-names>L</given-names></name>, <name><surname>McCullough</surname><given-names>AVP</given-names></name>, <name><surname>Kushi</surname><given-names>Lawrence H.</given-names></name>, <name><surname>Patel</surname><given-names>Roshni</given-names></name>, <name><surname>Willett</surname><given-names>Walter C.</given-names></name>, <name><surname>Doyle</surname><given-names>Colleen</given-names></name>, <name><surname>Thun</surname><given-names>Michael J.</given-names></name>, <name><surname>Gapstur</surname><given-names>Susan M.</given-names></name>, <article-title>Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease, and all-cause mortality</article-title>, <source>Cancer Epidemiol. Biomark. Prev</source><volume>20</volume> (<issue>6</issue>) (<year>2011</year>) <fpage>1089</fpage>–<lpage>1097</lpage>. Epub April 5, 2011, <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-10-1173</pub-id>.</mixed-citation>
              </ref>
              <ref id="R5">
                <label>[5]</label>
                <mixed-citation publication-type="journal"><name><surname>Hastert</surname><given-names>Theresa A.</given-names></name>, <name><surname>B</surname><given-names>SAA</given-names></name>, <name><surname>Patterson</surname><given-names>Ruth E.</given-names></name>, <name><surname>Kristal</surname><given-names>Alan R.</given-names></name>, <name><surname>White</surname><given-names>Emily</given-names></name>, <article-title>Adherence to WCRF/AICR cancer prevention recommendations and risk of postmenopausal breast cancer</article-title>, <source>Cancer Epidemiol. Biomark. Prev</source><volume>22</volume> (<issue>9</issue>) (<year>2013</year>) <fpage>1498</fpage>–<lpage>1508</lpage>. Epub June 18, 2013, <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-13-0210</pub-id>.</mixed-citation>
              </ref>
              <ref id="R6">
                <label>[6]</label>
                <mixed-citation publication-type="journal"><name><surname>Bruno</surname><given-names>Eleonora</given-names></name>, <name><surname>Gargano</surname><given-names>Giuliana</given-names></name>, <name><surname>Villarini</surname><given-names>Anna</given-names></name>, <name><surname>Traina</surname><given-names>Adele</given-names></name>, <name><surname>Johansson</surname><given-names>Harriet</given-names></name>, <name><surname>Mano</surname><given-names>Maria Piera</given-names></name>, <etal/>, <article-title>Adherence to WCRF/AICR cancer prevention recommendations and metabolic syndrome in breast cancer patients</article-title>, <source>Int. J. Cancer</source><volume>138</volume> (<issue>1</issue>) (<year>2016</year>) <fpage>237</fpage>–<lpage>244</lpage>. Epub 28 July 2015, <pub-id pub-id-type="doi">10.1002/ijc.29689</pub-id>.<pub-id pub-id-type="pmid">26175188</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>[7]</label>
                <mixed-citation publication-type="journal"><name><surname>Maki Inoue-Choi</surname><given-names>DL</given-names></name>, <name><surname>Prizment</surname><given-names>Anna E.</given-names></name>, <name><surname>Robien</surname><given-names>Kim</given-names></name>, <article-title>Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations for cancer prevention is associated with better health-related quality of life among elderly female cancer survivors</article-title>, <source>J. Clin. Oncol</source><volume>31</volume> (<issue>14</issue>) (<year>2013</year>) <fpage>1758</fpage>–<lpage>1766</lpage>. Epub April 8, 2013, <pub-id pub-id-type="doi">10.1200/JCO.2012.45.4462</pub-id>.<pub-id pub-id-type="pmid">23569318</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>[8]</label>
                <mixed-citation publication-type="journal"><name><surname>Thomson</surname><given-names>CA</given-names></name>, <name><surname>McCullough</surname><given-names>ML</given-names></name>, <name><surname>Wertheim</surname><given-names>BC</given-names></name>, <name><surname>Chlebowski</surname><given-names>RT</given-names></name>, <name><surname>Martinez</surname><given-names>ME</given-names></name>, <name><surname>Stefanick</surname><given-names>ML</given-names></name>, <etal/>, <article-title>Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women’s health initiative</article-title>, <source>Cancer Prev. Res. (Philadelphia, Pa)</source><volume>7</volume> (<issue>1</issue>) (<year>2014</year>) <fpage>42</fpage>–<lpage>53</lpage>. Epub 2014/01/10, <pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-13-0258</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>[9]</label>
                <mixed-citation publication-type="journal"><name><surname>Neugut</surname><given-names>AI</given-names></name>, <name><surname>Hillyer</surname><given-names>GC</given-names></name>, <name><surname>Kushi</surname><given-names>LH</given-names></name>, <name><surname>Lamerato</surname><given-names>L</given-names></name>, <name><surname>Buono</surname><given-names>DL</given-names></name>, <name><surname>Nathanson</surname><given-names>SD</given-names></name>, <etal/>, <article-title>A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL)</article-title>, <source>Breast Cancer Res. Treat</source><volume>158</volume> (<issue>1</issue>) (<year>2016</year>) <fpage>127</fpage>–<lpage>138</lpage>. Epub 2016/06/12, <pub-id pub-id-type="doi">10.1007/s10549-016-3855-3</pub-id><pub-id pub-id-type="pmid">27287779</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>[10]</label>
                <mixed-citation publication-type="journal"><name><surname>Hershman</surname><given-names>D</given-names></name>, <name><surname>McBride</surname><given-names>R</given-names></name>, <name><surname>Jacobson</surname><given-names>JS</given-names></name>, <name><surname>Lamerato</surname><given-names>L</given-names></name>, <name><surname>Roberts</surname><given-names>K</given-names></name>, <name><surname>Grann</surname><given-names>VR</given-names></name>, <etal/>, <article-title>Racial disparities in treatment and survival among women with early-stage breast cancer</article-title>, <source>J. Clin. Oncol</source><volume>23</volume> (<issue>27</issue>) (<year>2005</year>) <fpage>6639</fpage>–<lpage>6646</lpage>. Epub 2005/09/20, <pub-id pub-id-type="doi">10.1200/JCO.2005.12.633</pub-id><pub-id pub-id-type="pmid">16170171</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>[11]</label>
                <mixed-citation publication-type="journal"><name><surname>Bonadonna</surname><given-names>G</given-names></name>, <name><surname>Valagussa</surname><given-names>P</given-names></name>, <name><surname>Moliterni</surname><given-names>A</given-names></name>, <name><surname>Zambetti</surname><given-names>M</given-names></name>, <name><surname>Brambilla</surname><given-names>C</given-names></name>, <article-title>Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up</article-title>, <source>N. Engl. J. Med</source><volume>332</volume> (<issue>14</issue>) (<year>1995</year>) <fpage>901</fpage>–<lpage>906</lpage>. Epub 1995/04/06, <pub-id pub-id-type="doi">10.1056/NEJM199504063321401</pub-id><pub-id pub-id-type="pmid">7877646</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>[12]</label>
                <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Yu</surname><given-names>Q</given-names></name>, <name><surname>Wu</surname><given-names>XC</given-names></name>, <name><surname>Hsieh</surname><given-names>MC</given-names></name>, <name><surname>Loch</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>VW</given-names></name>, <etal/>, <article-title>Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2− vs. triple-negative</article-title>, <source>Breast Cancer Res. Treat</source><volume>169</volume> (<issue>1</issue>) (<year>2018</year>) <fpage>175</fpage>–<lpage>187</lpage>. Epub 2018/01/26, <pub-id pub-id-type="doi">10.1007/s10549-017-4646-1</pub-id>
<pub-id pub-id-type="pmid">29368311</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>[13]</label>
                <mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>JQ</given-names></name>, <name><surname>Wang</surname><given-names>SM</given-names></name>, <name><surname>Tang</surname><given-names>LL</given-names></name>, <name><surname>Mao</surname><given-names>J</given-names></name>, <name><surname>Wu</surname><given-names>YH</given-names></name>, <name><surname>Hai</surname><given-names>J</given-names></name>, <etal/>, <article-title>Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy</article-title>, <source>Breast Cancer Res. Treat</source><volume>151</volume> (<issue>2</issue>) (<year>2015</year>) <fpage>405</fpage>–<lpage>413</lpage>. Epub 2015/05/10.<pub-id pub-id-type="pmid">25956059</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>[14]</label>
                <mixed-citation publication-type="journal"><collab>Early Breast Cancer Trialists’ Collaborative G</collab>, <article-title>Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials</article-title>, <source>Lancet</source><volume>393</volume> (<issue>10179</issue>) (<year>2019</year>) <fpage>1440</fpage>–<lpage>1452</lpage>. Epub 2019/02/12, <pub-id pub-id-type="doi">10.1016/S0140-6736(18)33137-4</pub-id><pub-id pub-id-type="pmid">30739743</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>[15]</label>
                <mixed-citation publication-type="journal"><name><surname>Usiskin</surname><given-names>I</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <name><surname>Irwin</surname><given-names>ML</given-names></name>, <name><surname>Cartmel</surname><given-names>B</given-names></name>, <name><surname>Sanft</surname><given-names>T</given-names></name>, <article-title>Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer</article-title>, <source>Breast Cancer (Tokyo, Japan)</source><volume>26</volume> (<issue>6</issue>) (<year>2019</year>) <fpage>719</fpage>–<lpage>728</lpage>. Epub 2019/05/24, <pub-id pub-id-type="doi">10.1007/s12282-019-00974-3</pub-id><pub-id pub-id-type="pmid">31119682</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>[16]</label>
                <mixed-citation publication-type="journal"><name><surname>Powell</surname><given-names>HS</given-names></name>, <name><surname>Greenberg</surname><given-names>DL</given-names></name>, <article-title>Screening for unhealthy diet and exercise habits: the electronic health record and a healthier population</article-title>, <source>Prev. Med. Rep</source><volume>14</volume> (<year>2019</year>), <fpage>100816</fpage>. Epub 2019/03/01, <pub-id pub-id-type="doi">10.1016/j.pmedr.2019.01.020</pub-id><pub-id pub-id-type="pmid">30815334</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>[17]</label>
                <mixed-citation publication-type="journal"><name><surname>Irwin</surname><given-names>Melinda L.</given-names></name>, <name><surname>Cadmus</surname><given-names>Lisa</given-names></name>, <name><surname>Mierzejewski</surname><given-names>Eileen</given-names></name>, <name><surname>Mayne</surname><given-names>Susan T.</given-names></name>, <name><surname>Yu</surname><given-names>Herbert</given-names></name>, <name><surname>Chung</surname><given-names>Gina G.</given-names></name>, <name><surname>Jones</surname><given-names>Beth</given-names></name>, <name><surname>Knobf</surname><given-names>M. Tish</given-names></name>, <name><surname>DiPietro</surname><given-names>Loretta</given-names></name>, <article-title>Randomized controlled exercise trial on body fat, lean mass, and bone mineral density in breast cancer survivors: the Yale Exercise and Survivorship Study</article-title>, <source>Obesity (Silver Spring, Md)</source><volume>17</volume> (<issue>8</issue>) (<year>2009</year>) <fpage>1534</fpage>–<lpage>1541</lpage>. Epub March 18, 2010, <pub-id pub-id-type="doi">10.1038/oby.2009.18</pub-id>.<pub-id pub-id-type="pmid">19629060</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>[18]</label>
                <mixed-citation publication-type="journal"><name><surname>Harrigan</surname><given-names>M</given-names></name>, <name><surname>Cartmel</surname><given-names>B</given-names></name>, <name><surname>Loftfield</surname><given-names>E</given-names></name>, <name><surname>Sanft</surname><given-names>T</given-names></name>, <name><surname>Chagpar</surname><given-names>AB</given-names></name>, <name><surname>Zhou</surname><given-names>Y</given-names></name>, <etal/>, <article-title>Randomized trial comparing telephone versus in-person weight loss counseling on body composition and circulating biomarkers in women treated for breast cancer: the Lifestyle, Exercise, and Nutrition (LEAN) study</article-title>, <source>J. Clin. Oncol</source><volume>34</volume> (<issue>7</issue>) (<year>2016</year>) <fpage>669</fpage>–<lpage>676</lpage>. Epub 2015/11/26, <pub-id pub-id-type="doi">10.1200/JCO.2015.61.6375</pub-id>
<pub-id pub-id-type="pmid">26598750</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>[19]</label>
                <mixed-citation publication-type="journal"><name><surname>Knowler</surname><given-names>WC</given-names></name>, <name><surname>Barrett-Connor</surname><given-names>E</given-names></name>, <name><surname>Fowler</surname><given-names>SE</given-names></name>, <name><surname>Hamman</surname><given-names>RF</given-names></name>, <name><surname>Lachin</surname><given-names>JM</given-names></name>, <name><surname>Walker</surname><given-names>EA</given-names></name>, <etal/>, <article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</article-title>, <source>New Engl. J. Med</source><volume>346</volume> (<issue>6</issue>) (<year>2002</year>) <fpage>393</fpage>–<lpage>403</lpage>. Epub 2002/02/08, <pub-id pub-id-type="doi">10.1056/NEJMoa012512</pub-id>
<pub-id pub-id-type="pmid">11832527</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>[20]</label>
                <mixed-citation publication-type="book"><source>nutrition</source>. <publisher-name>CoDRBcaasio</publisher-name>. Available from: <comment><ext-link xlink:href="http://www.cdrnet.org/certifications/board-certification-as-a-specialistin-oncology-nutrition" ext-link-type="uri">http://www.cdrnet.org/certifications/board-certification-as-a-specialistin-oncology-nutrition</ext-link></comment>.</mixed-citation>
              </ref>
              <ref id="R21">
                <label>[21]</label>
                <mixed-citation publication-type="journal"><name><surname>Irwin</surname><given-names>ML</given-names></name>, <name><surname>Cartmel</surname><given-names>B</given-names></name>, <name><surname>Harrigan</surname><given-names>M</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <name><surname>Sanft</surname><given-names>T</given-names></name>, <name><surname>Shockro</surname><given-names>L</given-names></name>, <etal/>, <article-title>Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors</article-title>, <source>Cancer</source><volume>123</volume> (<issue>7</issue>) (<year>2017</year>) <fpage>1249</fpage>–<lpage>1258</lpage>. Epub 2016/11/29, <pub-id pub-id-type="doi">10.1002/cncr.30456</pub-id>
<pub-id pub-id-type="pmid">27893938</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>[22]</label>
                <mixed-citation publication-type="journal"><name><surname>Longo</surname><given-names>DL</given-names></name>, <name><surname>Duffey</surname><given-names>PL</given-names></name>, <name><surname>DeVita</surname><given-names>VT</given-names><suffix>Jr.</suffix></name>, <name><surname>Wesley</surname><given-names>MN</given-names></name>, <name><surname>Hubbard</surname><given-names>SM</given-names></name>, <name><surname>Young</surname><given-names>RC</given-names></name>, <article-title>The calculation of actual or received dose intensity: a comparison of published methods</article-title>, <source>J. Clin. Oncol</source><volume>9</volume> (<issue>11</issue>) (<year>1991</year>) <fpage>2042</fpage>–<lpage>2051</lpage>. Epub 1991/11/11, <pub-id pub-id-type="doi">10.1200/JCO.1991.9.11.2042</pub-id>
<pub-id pub-id-type="pmid">1941063</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>[23]</label>
                <mixed-citation publication-type="journal"><name><surname>Patterson</surname><given-names>RE</given-names></name>, <name><surname>Kristal</surname><given-names>AR</given-names></name>, <name><surname>Tinker</surname><given-names>LF</given-names></name>, <name><surname>Carter</surname><given-names>RA</given-names></name>, <name><surname>Bolton</surname><given-names>MP</given-names></name>, <name><surname>Agurs-Collins</surname><given-names>T</given-names></name>, <article-title>Measurement characteristics of the Women’s Health Initiative food frequency questionnaire</article-title>, <source>Ann. Epidemiol</source><volume>9</volume> (<issue>3</issue>) (<year>1999</year>) <fpage>178</fpage>–<lpage>187</lpage>. Epub 1999/04/07, <pub-id pub-id-type="doi">10.1016/s1047-2797(98)00055-6</pub-id>
<pub-id pub-id-type="pmid">10192650</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>[24]</label>
                <mixed-citation publication-type="journal"><name><surname>Kriska</surname><given-names>AM</given-names></name>, <name><surname>Knowler</surname><given-names>WC</given-names></name>, <name><surname>LaPorte</surname><given-names>RE</given-names></name>, <name><surname>Drash</surname><given-names>AL</given-names></name>, <name><surname>Wing</surname><given-names>RR</given-names></name>, <name><surname>Blair</surname><given-names>SN</given-names></name>, <etal/>, <article-title>Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians</article-title>, <source>Diabetes Care</source><volume>13</volume> (<issue>4</issue>) (<year>1990</year>) <fpage>401</fpage>–<lpage>411</lpage>. Epub 1990/04/01, <pub-id pub-id-type="doi">10.2337/diacare.13.4.401</pub-id><pub-id pub-id-type="pmid">2318100</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>[25]</label>
                <mixed-citation publication-type="journal"><name><surname>Cartmel</surname><given-names>B</given-names></name>, <name><surname>Anderson</surname><given-names>C</given-names></name>, <name><surname>Irwin</surname><given-names>ML</given-names></name>, <name><surname>Harrigan</surname><given-names>M</given-names></name>, <name><surname>Sanft</surname><given-names>T</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <etal/>, <article-title>Skin carotenoids are inversely associated with adiposity in breast cancer survivors</article-title>, <source>Nutr. Res</source><volume>79</volume> (<year>2020</year>) <fpage>77</fpage>–<lpage>86</lpage>. Epub 2020/07/11, <pub-id pub-id-type="doi">10.1016/j.nutres.2020.05.012</pub-id><pub-id pub-id-type="pmid">32650223</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>[26]</label>
                <mixed-citation publication-type="journal"><name><surname>Ziller</surname><given-names>V</given-names></name>, <name><surname>Kyvernitakis</surname><given-names>I</given-names></name>, <name><surname>Knoll</surname><given-names>D</given-names></name>, <name><surname>Storch</surname><given-names>A</given-names></name>, <name><surname>Hars</surname><given-names>O</given-names></name>, <name><surname>Hadji</surname><given-names>P</given-names></name>, <article-title>Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment—the COMPAS study</article-title>, <source>BMC Cancer</source><volume>13</volume> (<year>2013</year>) <fpage>407</fpage>. Epub 2013/09/07, <pub-id pub-id-type="doi">10.1186/1471-2407-13-407</pub-id>
<pub-id pub-id-type="pmid">24006873</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>[27]</label>
                <mixed-citation publication-type="journal"><name><surname>Gehi</surname><given-names>A</given-names></name>, <name><surname>Haas</surname><given-names>D</given-names></name>, <name><surname>Pipkin</surname><given-names>S</given-names></name>, <name><surname>Whooley</surname><given-names>MA</given-names></name>, <article-title>Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study</article-title>, <source>Arch. Intern. Med</source><volume>165</volume> (<issue>21</issue>) (<year>2005</year>) <fpage>2508</fpage>–<lpage>2513</lpage>, <pub-id pub-id-type="doi">10.1001/archinte.165.21.2508</pub-id><pub-id pub-id-type="pmid">16314548</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>[28]</label>
                <mixed-citation publication-type="journal"><name><surname>van Waart</surname><given-names>H</given-names></name>, <name><surname>Stuiver</surname><given-names>MM</given-names></name>, <name><surname>van Harten</surname><given-names>WH</given-names></name>, <name><surname>Geleijn</surname><given-names>E</given-names></name>, <name><surname>Kieffer</surname><given-names>JM</given-names></name>, <name><surname>Buffart</surname><given-names>LM</given-names></name>, <etal/>, <article-title>Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial</article-title>, <source>J. Clin. Oncol</source><volume>33</volume> (<issue>17</issue>) (<year>2015</year>) <fpage>1918</fpage>–<lpage>1927</lpage>. Epub 2015/04/29, <pub-id pub-id-type="doi">10.1200/JCO.2014.59.1081</pub-id><pub-id pub-id-type="pmid">25918291</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>[29]</label>
                <mixed-citation publication-type="journal"><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>S</surname><given-names>R</given-names></name>, <name><surname>Mackey</surname><given-names>JR</given-names></name>, <name><surname>Gelmon</surname><given-names>K</given-names></name>, <name><surname>Reid</surname><given-names>RD</given-names></name>, <name><surname>Friedenreich</surname><given-names>CM</given-names></name>, <name><surname>Ladha</surname><given-names>AB</given-names></name>, <name><surname>Proulx</surname><given-names>C</given-names></name>, <name><surname>Vallance</surname><given-names>JK</given-names></name>, <name><surname>Lane</surname><given-names>K</given-names></name>, <name><surname>Yasui</surname><given-names>Y</given-names></name>, <name><surname>McKenzie</surname><given-names>DC</given-names></name>, <article-title>Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial</article-title>, <source>J. Clin. Oncol</source><volume>25</volume> (<issue>28</issue>) (<year>2007</year>) <fpage>4396</fpage>–<lpage>4404</lpage>. Epub 2007 Sep 4, <pub-id pub-id-type="doi">10.1200/JCO.2006.08.2024</pub-id>.<pub-id pub-id-type="pmid">17785708</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>[30]</label>
                <mixed-citation publication-type="journal"><name><surname>Carayol</surname><given-names>M</given-names></name>, <name><surname>Ninot</surname><given-names>G</given-names></name>, <name><surname>Senesse</surname><given-names>P</given-names></name>, <name><surname>Bleuse</surname><given-names>JP</given-names></name>, <name><surname>Gourgou</surname><given-names>S</given-names></name>, <name><surname>Sancho-Garnier</surname><given-names>H</given-names></name>, <etal/>, <article-title>Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the “APAD1” randomized controlled trial</article-title>, <source>BMC Cancer</source><volume>19</volume> (<issue>1</issue>) (<year>2019</year>) <fpage>737</fpage>. Epub 2019/07/28, <pub-id pub-id-type="doi">10.1186/s12885-019-5896-6</pub-id><pub-id pub-id-type="pmid">31345179</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>[31]</label>
                <mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>Y</given-names></name>, <name><surname>Irwin</surname><given-names>ML</given-names></name>, <name><surname>Ferrucci</surname><given-names>LM</given-names></name>, <name><surname>McCorkle</surname><given-names>R</given-names></name>, <name><surname>Ercolano</surname><given-names>EA</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <etal/>, <article-title>Health-related Quality of Life in Ovarian Cancer Survivors: Results From the American Cancer Society’s Study of Cancer Survivors - I</article-title>. <source>Gynecologic Oncology</source><volume>141</volume>(<issue>3</issue>), <year>2016</year>, pp. <fpage>543</fpage>–<lpage>549</lpage>. Epub 2016/04/14, <pub-id pub-id-type="doi">10.1016/j.ygyno.2016.04.006</pub-id>
<pub-id pub-id-type="pmid">27072805</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>[32]</label>
                <mixed-citation publication-type="journal"><name><surname>Postma</surname><given-names>TJ</given-names></name>, <name><surname>Aaronson</surname><given-names>NK</given-names></name>, <name><surname>Heimans</surname><given-names>JJ</given-names></name>, <name><surname>Muller</surname><given-names>MJ</given-names></name>, <name><surname>Hildebrand</surname><given-names>JG</given-names></name>, <name><surname>Delattre</surname><given-names>JY</given-names></name>, <etal/>, <article-title>The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20</article-title>, <source>Eur. J. Cancer</source><volume>41</volume> (<issue>8</issue>) (<year>2005</year>) <fpage>1135</fpage>–<lpage>1139</lpage>, <pub-id pub-id-type="doi">10.1016/j.ejca.2005.02.012</pub-id><pub-id pub-id-type="pmid">15911236</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>[33]</label>
                <mixed-citation publication-type="journal"><name><surname>Stanton</surname><given-names>AL</given-names></name>, <name><surname>Bernaards</surname><given-names>CA</given-names></name>, <name><surname>Ganz</surname><given-names>PA</given-names></name>, <article-title>The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer</article-title>, <source>J. Natl. Cancer Inst</source><volume>97</volume> (<issue>6</issue>) (<year>2005</year>) <fpage>448</fpage>–<lpage>456</lpage>, <pub-id pub-id-type="doi">10.1093/jnci/dji069</pub-id>
<pub-id pub-id-type="pmid">15770009</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>[34]</label>
                <mixed-citation publication-type="journal"><name><surname>Atkinson</surname><given-names>TM</given-names></name>, <name><surname>Rosenfeld</surname><given-names>BD</given-names></name>, <name><surname>Sit</surname><given-names>L</given-names></name>, <name><surname>Mendoza</surname><given-names>TR</given-names></name>, <name><surname>Fruscione</surname><given-names>M</given-names></name>, <name><surname>Lavene</surname><given-names>D</given-names></name>, <etal/>, <article-title>Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI)</article-title>, <source>J. Pain Symptom Manag</source><volume>41</volume> (<issue>3</issue>) (<year>2011</year>) <fpage>558</fpage>–<lpage>565</lpage>, <pub-id pub-id-type="doi">10.1016/j.jpainsymman.2010.05.008.21131166</pub-id>.</mixed-citation>
              </ref>
              <ref id="R35">
                <label>[35]</label>
                <mixed-citation publication-type="journal"><name><surname>Horne</surname><given-names>Robert</given-names></name>, <article-title>The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication</article-title>, <source>Psychol. Health</source><volume>14</volume> (<issue>1</issue>) (<year>1999</year>) <fpage>1</fpage>–<lpage>24</lpage>. Epub 19 December 2007, <pub-id pub-id-type="doi">10.1080/08870449908407311</pub-id>.</mixed-citation>
              </ref>
              <ref id="R36">
                <label>[36]</label>
                <mixed-citation publication-type="journal"><name><surname>Atkinson</surname><given-names>MJ</given-names></name>, <name><surname>Sinha</surname><given-names>A</given-names></name>, <name><surname>Hass</surname><given-names>SL</given-names></name>, <name><surname>Colman</surname><given-names>SS</given-names></name>, <name><surname>Kumar</surname><given-names>RN</given-names></name>, <name><surname>Brod</surname><given-names>M</given-names></name>, <etal/>, <article-title>Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease</article-title>, <source>Health Qual. Life Outcomes</source><volume>2</volume> (<year>2004</year>) <fpage>12</fpage>, <pub-id pub-id-type="doi">10.1186/1477-7525-2-12.14987333</pub-id>.<pub-id pub-id-type="pmid">14987333</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>[37]</label>
                <mixed-citation publication-type="journal"><name><surname>Norman</surname><given-names>SA</given-names></name>, <name><surname>Miller</surname><given-names>LT</given-names></name>, <name><surname>Erikson</surname><given-names>HB</given-names></name>, <name><surname>Norman</surname><given-names>MF</given-names></name>, <name><surname>McCorkle</surname><given-names>R</given-names></name>, <article-title>Development and validation of a telephone questionnaire to characterize lymphedema in women treated for breast cancer</article-title>, <source>Phys. Ther</source><volume>81</volume> (<issue>6</issue>) (<year>2001</year>) <fpage>1192</fpage>–<lpage>1205</lpage> (Epub 2001/05/31.).<pub-id pub-id-type="pmid">11380275</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>[38]</label>
                <mixed-citation publication-type="book"><name><surname>Allison</surname><given-names>PD</given-names></name>, <part-title>Paper 213–2012. Handling Missing Data by Maximum Likelihood</part-title>. <source>SAS Global Forum 2012</source>, <publisher-name>SAS Institute Inc</publisher-name>, <publisher-loc>Cary, NC</publisher-loc>, <year>2012</year>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig position="float" id="F1">
              <label>Fig. 1.</label>
              <caption>
                <p id="P84">The <underline>L</underline>ifestyle, <underline>E</underline>xercise, and <underline>N</underline>utrition <underline>Ear</underline>ly after Diagnosis (LEANer) study schema.</p>
              </caption>
              <graphic xlink:href="nihms-1920049-f0001" position="float"/>
            </fig>
            <fig position="float" id="F2">
              <label>Fig. 2.</label>
              <caption>
                <p id="P85">The LEANer study schedule of enrollment, interventions, and assessments.</p>
              </caption>
              <graphic xlink:href="nihms-1920049-f0002" position="float"/>
            </fig>
            <table-wrap position="float" id="T1">
              <label>Table 1</label>
              <caption>
                <p id="P86">Eligibility criteria.</p>
              </caption>
              <table frame="hsides" rules="none">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <tbody>
                  <tr>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">Inclusion criteria</th>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Diagnosed with Stage I-III breast cancer</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Adjuvant or neoadjuvant chemotherapy is part of breast cancer treatment</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Physically able to walk</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Able to complete forms and understand instructions in English</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Agrees to be randomly assigned to either intervention or usual care group</td>
                  </tr>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">
                      <underline>Exclusion criteria</underline>
                    </th>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Received their second chemotherapy infusion</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Eating 7 or more fruits and vegetables a day</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Doing 150 or more minutes per /week of moderate to vigorous intensity physical activity or 75 min/week of vigorous-intensity physical activity</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Are pregnant or intending to become pregnant in the next year</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Recent (past year) stroke/myocardial infarction or congestive heart failure</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Presence of dementia or major psychiatric disease</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Are malnourished (PG-SGA assessment)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Participating in a meal replacement weight loss program</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
            <table-wrap position="float" id="T2">
              <label>Table 2</label>
              <caption>
                <p id="P87">Lifestyle guidelines.</p>
              </caption>
              <table frame="hsides" rules="none">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <tbody>
                  <tr>
                    <th align="left" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">Dietary guidelines</th>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Eat a combination of 7+ fruits and/or vegetables servings/day</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Reduce simple sugars</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Limit consumption of processed and red meats to ≤18 oz/week</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Limit alcohol consumption to 1drink/day or 8 drinks/week</td>
                  </tr>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Physical activity guidelines</th>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• 150+ min/week of moderate to vigorous intensity physical activity or 75 min/week of vigorous-intensity physical activity</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Twice-weekly strength training</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">• Reduce sedentary time</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
